Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROCTFUL: Pre-operative Oxaliplatin, Capecitabine and Radiotherapy in Rectal Cancer
NCT00263029Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jun 2002
- Primary completion
- Mar 2007
- Modality
- DNA Intercalators/Alkylators
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin in rectal cancer, sponsored by Sanofi. Primary endpoints: Response rate (clinical and pathological), Histologically confirmed complete resection rate (R0 rate) and 2 more. Started Jun 2002; status: completed.
02
Drugs
oxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT00263029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00263029.